FRA:APPH - Deutsche Boerse Ag - DE000A3CMGM5 - Common Stock - Currency: EUR
FRA:APPH (4/25/2025, 7:00:00 PM)
11.2
-0.25 (-2.18%)
The current stock price of APPH.DE is 11.2 EUR. In the past month the price decreased by -0.44%. In the past year, price increased by 38.96%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY.DE | ELI LILLY & CO | 66.68 | 722.56B | ||
1LLY.MI | ELI LILLY & CO | 65.4 | 708.62B | ||
ZEG.DE | ASTRAZENECA PLC | 16.88 | 377.93B | ||
JNJ.DE | JOHNSON & JOHNSON | 15.27 | 324.94B | ||
NOV.DE | NOVO NORDISK A/S-B | 17.94 | 241.31B | ||
SNW.DE | SANOFI | 12.07 | 226.94B | ||
SAN.PA | SANOFI | 13.72 | 226.10B | ||
6MK.DE | MERCK & CO. INC. | 10.34 | 174.89B | ||
1MRKX.MI | MERCK & CO. INC. | 10.16 | 171.87B | ||
PFE.DE | PFIZER INC | 7.36 | 113.97B | ||
1PFE.MI | PFIZER INC | 7.17 | 111.02B | ||
BRM.DE | BRISTOL-MYERS SQUIBB CO | 41.5 | 84.44B |
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 177 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
APONTIS PHARMA AG
Rolf-Schwarz-Schuette-Platz 1
Monheim Am Rhein NORDRHEIN-WESTFALEN DE
Employees: 177
Company Website: https://www.apontis-pharma.de
Investor Relations: http://www.apontis-pharma.de/en/investor-relations
The current stock price of APPH.DE is 11.2 EUR. The price decreased by -2.18% in the last trading session.
The exchange symbol of APONTIS PHARMA AG is APPH and it is listed on the Deutsche Boerse Ag exchange.
APPH.DE stock is listed on the Deutsche Boerse Ag exchange.
12 analysts have analysed APPH.DE and the average price target is 14.62 EUR. This implies a price increase of 30.54% is expected in the next year compared to the current price of 11.2. Check the APONTIS PHARMA AG stock analysts ratings, price target forecast and up-and down grades for more detailed information.
APONTIS PHARMA AG (APPH.DE) has a market capitalization of 95.20M EUR. This makes APPH.DE a Micro Cap stock.
APONTIS PHARMA AG (APPH.DE) currently has 177 employees.
APONTIS PHARMA AG (APPH.DE) has a support level at 11.14 and a resistance level at 11.25. Check the full technical report for a detailed analysis of APPH.DE support and resistance levels.
The Revenue of APONTIS PHARMA AG (APPH.DE) is expected to grow by 37.73% in the next year. Check the estimates tab for more information on the APPH.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
APPH.DE does not pay a dividend.
APONTIS PHARMA AG (APPH.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.76).
ChartMill assigns a technical rating of 8 / 10 to APPH.DE. When comparing the yearly performance of all stocks, APPH.DE is one of the better performing stocks in the market, outperforming 93.5% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to APPH.DE. While APPH.DE has a great health rating, there are worries on its profitability.
Over the last trailing twelve months APPH.DE reported a non-GAAP Earnings per Share(EPS) of -0.76. The EPS decreased by -520.42% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -14.5% | ||
ROE | -21.16% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 43% to APPH.DE. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 106.38% and a revenue growth 37.73% for APPH.DE